Headquarters
USA

Earli

Earli locates cancer early, when it is much more curable. Rather than rely on biomarkers that cancer may – or often may not – naturally provide, Earli's technology “forces” cancer cells to make a precise synthetic, non-human biomarker to localize the cancer. This new approach is called synthetic biopsy. In the future, the same platform might also be usable to trigger localized therapeutic responses inside the cancer.

Visit the Earli website
About Us
Events
Media
Partners & Members
Language Editions

Privacy Policy & Terms of Service

© 2022 World Economic Forum